Akari Therapeutics Plc
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(12,000) | $(16,019) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | — | 13 |
| Stock-based compensation | 2,419 | 989 |
| Issuance of share capital for payments in kind | 27 | — |
| Accretion of debt issuance costs on notes payable and notes payable, related party | 93 | — |
| Gain on settlement of current liabilities | (2,018) | — |
| Loss on debt extinguishment | 967 | — |
| Change in fair value of warrant liabilities | (333) | (528) |
| Impairment loss on other intangible assets | 5,180 | — |
| Loss on derivative liability | 100 | — |
| Deferred tax benefit | (1,088) | — |
| Unrealized foreign currency exchange (gains) losses | (450) | 121 |
| Change in assets and liabilities: | ||
| Prepaid expenses and other current assets | 392 | 1,114 |
| Accounts payable and accrued expenses | (816) | 3,882 |
| Net cash used in operating activities | (7,527) | (10,428) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of shares, net of issuance costs | 5,879 | 8,687 |
| Proceeds from issuance of convertible notes | — | 1,000 |
| Proceeds from issuance of notes payable | 2,099 | — |
| Proceeds from employee vesting of restricted shares | 33 | 29 |
| Proceeds from pre-funded warrants | 330 | — |
| Repayments of notes payable | (488) | — |
| Payments on short-term financing arrangement | (442) | (882) |
| Net cash provided by financing activities | 7,411 | 8,834 |
| Effect of exchange rates on cash | 1 | (5) |
| Net change in cash | (115) | (1,599) |
| Cash and restricted cash at beginning of period | 2,659 | 3,845 |
| Cash and restricted cash at end of period | $2,544 | $2,246 |
| Components of cash and restricted cash | ||
| Cash | $2,484 | $2,246 |
| Restricted cash | 60 | — |
| Total cash and restricted cash | $2,544 | $2,246 |
| SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: | ||
| Financing costs in accounts payable | $— | $72 |
| Issuance of share capital for settlement of convertible notes, related party | $309 | $— |
| Issuance of share capital for settlement of note payable, related party | $1,000 | $— |
| Issuance of share capital for payments in kind | $595 | $— |
| Seller-financed purchases | $499 | $1,105 |
| Modification of warrants in connection with issuance of notes payable | $2,643 | $— |
| Reclassification and modification of warrants in connection with amendment of convertible notes | $192 | $— |
| Payroll taxes on share-based compensation in accrued expenses | $— | $193 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES: | ||
| Cash paid for interest | $101 | $120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.